Quick Answer
Liminatus Pharma, Inc. reported Net Income of -$10.21 million for fiscal year 2025.
Liminatus Pharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Income | -$10.21M -187.8% |
-$3.55M | — |
| Diluted EPS | -$0.43 -115.0% |
-$0.20 | — |
| Total Assets | $512.8K -90.5% |
$5.41M | — |
| Stockholders Equity | -$9.81M +49.3% |
-$19.34M -22.5% |
-$15.79M |
| R&D Expense | — | $2.69M | — |
| Operating Income | -$2.97M +10.9% |
-$3.33M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$1.82M | -203.2% | -1709.5% |
| Diluted EPS | September 30, 2025 | -$0.07 | -133.3% | — |
| Total Assets | September 30, 2025 | $1.34M | — | -29.7% |
| Stockholders Equity | September 30, 2025 | -$1.65M | +91.4% | +81.3% |
| R&D Expense | September 30, 2024 | $357.1K | — | -50.0% |
| Operating Income | September 30, 2025 | -$701.2K | -29.1% | +37.3% |
- Liminatus Pharma, Inc. reported Net Income of -$10.21 million for fiscal year 2025.
- Liminatus Pharma, Inc. showed a decrease of -187.8% in Net Income compared to the prior fiscal year.
- Liminatus Pharma, Inc. reported Diluted EPS of $0.43 per share (loss) for fiscal year 2025.
- Liminatus Pharma, Inc. showed a decrease of -115.0% in Diluted EPS compared to the prior fiscal year.
- Liminatus Pharma, Inc. reported Total Assets of $512.8 thousand for fiscal year 2025.
- Liminatus Pharma, Inc. showed a decrease of -90.5% in Total Assets compared to the prior fiscal year.
- Liminatus Pharma, Inc. reported Stockholders Equity of -$9.81 million for fiscal year 2025.
- Liminatus Pharma, Inc. showed an increase of +49.3% in Stockholders Equity compared to the prior fiscal year.
- Liminatus Pharma, Inc. reported R&D Expense of $2.69 million for fiscal year 2024.
- Liminatus Pharma, Inc. reported Operating Income of -$2.97 million for fiscal year 2025.
- Liminatus Pharma, Inc. showed an increase of +10.9% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: